FCM
CGON icon

Farallon Capital Management’s CG Oncology CGON Stock Holding History

Farallon Capital Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.5M Buy
+200,000
New +$11.3M 0.08% 63

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Farallon Capital Management's CGON Position: Q1 2026 in Review

Farallon Capital Management increased its CG Oncology (CGON) stake by 8,325% in Q1 2026, buying an estimated $37.7M and bringing the position to 674,000 shares worth $45.6M. The position accounts for 0.26% of the portfolio, ranked #42.

Farallon Capital Management first reported a position in CGON in Q2 2025 and has held it in 4 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Farallon Capital Management held 674,000 shares of CG Oncology worth $45.6M as of Q1 2026.
  • Farallon Capital Management bought 666,000 CG Oncology shares in Q1 2026, an estimated $37.7M.
  • CG Oncology made up 0.26% of Farallon Capital Management's portfolio in Q1 2026, its #42 holding.
  • Farallon Capital Management first reported a position in CG Oncology in Q2 2025 and has held it in 4 quarters since.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.